Skip Navigation

Ann Kier

Professor

Send Email

Phone: (979) 862-1509

Mailstop: 4467

Department: VTPB

Photo of Kier, Ann

Education

  • Ph.D. Comparative Pathology, University of Missouri, Columbia 1979
  • Residency Laboratory Animal Medicine, University of Missouri, Columbia 1979
  • D.V.M. Veterinary Medicine, Texas A&M University 1974
  • B.S. Veterinary Science, Texas A&M University 1973
  • B.A. Zoology, University of Texas, Austin 1971

Credentials

  • American College of Laboratory Animal Medicine
  • Professor, Department of Veterinary Pathobiology, Texas Veterinary Medical Center, Texas A&M University, College Station, TX
  • Program Director, NIH T32 Post Doctoral Training grant
  • Program Director, NIH T35 Research Training Program for veterinary students
  • Program Director, NIH R25 Lab Animal Residency Training grant
  • Texas Veterinary Medical Specialty License: 0131-S

Scholarly Interests

The long-term goal of my research is to understand how regulation of lipids (cholesterol, saturated versus unsaturated fatty acids) and glucose affect the pathogenesis of cardiovascular disease and diabetes through the use of cultured primary hepatocytes (human, mouse), gene-ablated, overexpression, and humanized mice as models for understanding human conditions, and to use these discovered mechanisms to exploit new drug development. Our current projects include investigating whether an intracellular fatty acid binding protein L-FABP mediates fibrate signaling to hepatic PPAR alpha, an action potentiated by high glucose. Further, we propose that the human L-FABP T94A gene variant is impaired in its ability to function in this pathway, especially in the context of high glucose. We will be examining the collective physiologic impact of fibrates and human L-FABP T94A variant on signaling to PPAR alpha in a humanized mouse model in vivo. The impact of human L-FABP T94A variant and glucose on fibrate nuclear targeting for PPAR alpha interaction and activation is being examined via primary cultured human hepatocytes of WT and variant cells. I have the expertise, productivity, and interest needed to successfully carry out the proposed work. I am Director of a Transgenic Mouse Core Facility, and supervise the Injection and Morphology/Pathology Sections. I have a broad background in animal models, with specific training and expertise in key research areas in this application, including immunocytochemistry, primary hepatocyte culture, cell culture, construction of mammalian expression vectors, transfection, cloning of cells, in vivo lipid metabolism, and mouse phenotyping. As a Resident in Laboratory Animal Medicine and Postdoctoral Fellow in Comparative Pathology at the University of Missouri, I was trained in both human and laboratory animal pathology (comparative, experimental pathology) as well as earning Diplomate status in the American College of Laboratory Animal Medicine (ACLAM). At the University of Cincinnati Health Sciences Center, I furthered my expertise in animal models by learning gene-ablation techniques in the laboratory of Thomas Doetschman, collaborating on several NIH PO1 project grants as well as my own RO1 grants to clone the mouse gene coding for Hageman Factor and develop a genetically deficient mouse model. As Director of Comparative Pathology while teaching human pathology, I developed collaborations with Tom Doetschman, Steve Potter, Peter Stambrook, Jeffrey Robbins and other experts in the newly expanding field of mouse gene targeting to strengthen my expertise in mouse phenotyping and pathology, having PO1 components on 3 grants as well as PI and Co-I on RO1 grants, and publishing in Nature, Cell, J Biological Chemistry, and other high impact journals. While at Texas A&M University, I applied this expertise to develop and phenotype new mouse models overexpressing or ablated in genes encoding fatty acid and fatty acyl CoA binding proteins in collaboration with Dr. Friedhelm (Fred) Schroeder. The highly productive integration of different disciplines with the Dr. Friedhelm is particularly unique in our ability to follow key questions from the in vitro isolated protein level (Schroeder), through live cell culture imaging experiments (Schroeder and Kier), and in vivo into the molecular biological and physiologic environment of mouse models (Kier).

Publications

FABP1: a novel hepatic endocannabinoid and cannabinoid binding protein
Huang H, McIntosh A L, Martin GG, Landrock D, Chung S, Landrock KK, Dangott LJ, Li S, Kier AB, Schroeder F. FABP1
Biochemistry. 55: 5243-5255.
Female mice are resistant to FABP1 gene ablation-induced alterations in brain endocannabinoid levels
Martin GG, Chung S, Landrock D, Landrock KK, Dangott LJ, Peng X, Kaczocha M, Murphy EJ, Kier AB, and Schroeder F
Lipids . 51: 1007-1020.
Impact of high dietary phytol on lipid metabolism in female SCP-2/SCP-x/L-FABP null mice
Milligan S, Martin G, Landrock D, McIntosh AL, Schroeder F, Kier AB
Am J Physiol Gastrointest Liver Physiol.
Fabp1 gene ablation inhibits high fat diet-induced increase in brain endocannabinoids
Martin GG, Landrock D, Chung S, Dangott LJ, Seeger DR, Murphy EJ, Golovko MY, Kier AB, Schroeder F
J Neurochem.
Impact of L-FABP and glucose on polyunsaturated fatty acid induction of PPAR regulated -oxidative enzymes.
Petrescu AD, Huang H, Martin GG, McIntosh AL, Storey SM, Landrock D, Kier AB, Schroeder F.
Am J Physiol Gastrointest and Liver Phys . 304: G241-256.
Structural and functional interaction of fatty acids with human liver fatty acid binding protein (L-FABP) T94A variant.
Huang H, McIntosh AL, Martin GG, Landrock KK, Landrock D, Gupta S, Atshaves BP, Kier AB, Schroeder F:
FEBS J. 281:2266-2283.
Human L-FABP T94A variant alters structure, stability, and interaction with fibrates.
Martin GG, McIntosh AL, Huang H, Gupta S, Atshaves BP, Kier AB, Schroeder F.
Biochemistry. ID: bi-2013-01014k.
Liver fatty acid binding protein (L-FABP) gene ablation exacerbates weight gain in high-fat fed female mice.
McIntosh AL, Atshaves BP, Landrock D, Landrock KK, Martin GG, Storey SM, Kier AB, Schroeder F
Lipids . 48:435-448.
High glucose potentiates L-FABP-mediated fibrate induction of PPAR in mouse hepatocytes.
Petrescu AD, McIntosh AL, Storey SM, Huang H, Martin GG, Landrock D, Kier AB, Schroeder F.
Biochim Biophys Acta. 1831:1412-1425.
Inhibitors of fatty acid synthesis induce PPAR-regulated fatty acid -oxidative enzymes: synergistic roles of L-FABP and glucose
Huang H, McIntosh AL, Martin GG, Petrescu AD, Landrock K, Landrock D, Kier AB, Schroeder F.
PPAR Research . DOI: 10.1155/ 2013/865604. .
L-FABP interacts with HNF4
McIntosh AL, Petrescu AD, Hostetler HA, Kier AB, Schroeder F.
FEBS Letters. 587, D-13-01329.
Human FABP1 T94A variant impacts fatty acid metabolism and PPAR activation in cultured human female hepatocytes
McIntosh AL, Huang H, Storey SM, Landrock KK, Landrock D, Petrescu AD, Gupta S, Atshaves BP, Kier AB, Schroeder F:
Am J Physiol, Gast Liver Physiol . 307(2): G164-76. doi: 10.1152/ajpgi.00369.2013.
Acyl-CoA Binding Protein Gene Ablation Induces Pre-implantation Embryonic Lethality in Mice
Landrock, Danilo, Barbara P. Atshaves, Avery L. McIntosh, Kerstin K. Landrock, Friedhelm Schroeder, Ann B. Kier
Lipids. 45(7):567-80.
Ablating L-FABP in SCP-2/SCP-x null mice impairs bile acid metabolism and biliary HDL-cholesterol secretion
Martin GG, Atshaves BP, Landrock KK, Landrock D, Storey SM, Howles PN, Kier AB, Schroeder F
Am J Physiol. 307: G1130–G1143.
Human liver fatty acid binding protein (L-FABP) T94A variant enhances cholesterol uptake.
Huang H, McIntosh AL, Martin GG, Landrock KK, Landrock D, Storey, SM, Gupta S, Atshaves BP, Kier AB, Schroeder F
Biochim Biophys Acta 1851: 946-955. 1851: 946-955.
Loss of L-FABP, SCP-2/SCPx, or both induces hepatic lipid accumulation in female mice
Martin GG, Atshaves BP, Landrock KK, Landrock D, Schroeder F, Kier AB
Arch Biochem Biophys 580:41-49. 580: 41-49.
Relative contributions of L-FABP, SCP-2/SCP-x, or both to hepatic biliary phenotype of female mice
Martin GG, Landrock D, Landrock KK, Howles PN, Atshaves BP, Kier AB, Schroeder F
Arch Biochem Biophys. 580: 41-49.
SCP-SCP-x gene ablation exacerbates high-cholesterol induced hepatic lipid accumulation
Klipsic D, Landrock D, Martin GG, McIntosh AL Landrock KK, Mackie JT, Schroeder F, Kier AB
Am J Physiol Gastrointest Liver Physiol . 309: G387-G399.
FABP1 gene ablation impacts the brain endocannabinoid system in male mice
Martin G, Chung S, Landrock D, Landrock KK, Huang H, Dangott LJ, Peng X, Kaczocha M, Seeger DR, Murphy EJ, Golovko MY, Kier AB, and Schroeder F
J Neurochem . 138: 407-422.


Request Update